Sign inJoin waitlistJoin the waitlist

Craig Boddy

Assistant Professor, Department of Medicine · University of Hawaii John A Burns School of Medicine

Credentials: · · · · · · ·

History

Hematology and Medical Oncology
McGaw Medical Center of Northwestern University
2015–2018
Internal Medicine
Washington University School of Medicine
2012–2015
University of Illinois College of Medicine
2008–2012

Research

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
Review · OncoTargets and Therapy · 2016 · 59 citations
Oct4/Sox2 binding sites contribute to maintaining hypomethylation of the maternal igf2/h19 imprinting control region
PLoS ONE · 2013 · 35 citations
D-Glucose modulates intestinal Niemann-Pick C1-like 1 (NPC1L1) gene expression via transcriptional regulation
American Journal of Physiology-Gastrointestinal and Liver Physiology · 2013 · 23 citations

AB
Amir Behdad
1 paper
Barbara Pro
1 paper
Brent Tan
1 paper
Daniel Landsburg
1 paper
Emily Ayers
1 paper · 1 as a fellow
Hidayatullah Munshi
1 paper
Jane Winter
1 paper
JK
Jason Kaplan
1 paper
JA
Joseph Aoki
1 paper
Leo Gordon
1 paper
MF
Marissa Falkiewicz
1 paper · 1 as a resident
Qing Chen
1 paper

Clinical trials

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2029
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2017–2027